FUAT DEDE, TUNÇ ÖNEŞ, Sinem CANDEMİR, Fuad NOVRUZOV, Serkan GÜNGÖR, Mustafa ARAS, Salih ÖZGÜVEN, Sabahat İNANIR, Tanju Yusuf ERDİL, Halil Turgut TUROĞLU

Graves Hastalığı Tedavisinde Sabit 10 mCi ve 15 mCi İyot-131 Dozlarının Karşılaştırılması: 11 Yıllık Tecrübe

Amaç: Sabit doz Iyot-131 (RAI) tedavisi, karmaşık hesaplamalara ihtiyaç duymayan basit ancak etkin bir seçenektir. Bu çalışmada, Graves hastalığında sabit 10 ve 15 mCi ile RAI tedavisi sonuçları karşılaştırıldı. Hastalar ve Yöntem: 1997-2008 tarihleri arasında sabit 10 mCi (n:48) ve sabit 15 mCi (n:9) RAI tedavisi almış ve en az 2 yıl takip edilmiş 55 hastanın takip dosyaları incelenerek başarılı (ötiroidi, hipotiroidi) ve başarısız (persiste hipertiroidi) tedavi oranları ile sonuçlara etkili olabilecek parametreler analiz edildi. Bulgular: 10 mCi alan grupta tedavi başarı oranı %87 (ötiroidi %9.1, hipotiroidi %78.2) olarak bulunurken, 15 mCi alan grupta bu değer %100 (hipotiroidi) olarak bulundu. Her iki grup arasında, kullanılan ortalama propylthiouracil dozu dışında (10 mCi: 190 mg, 15 mCi: 350 mg, p<0.05) anlamlı fark izlenmedi. Sonuç: Sabit 10 ve 15 mCi RAI doz uygulamalarının her ikisi de Graves hastalığının tedavisinde başarılı sonuç vermiştir. Sabit 10 mCi verilen hastalarda düşük oranda da olsa persistan hipertiroidizm izlenebilmektedirAnahtar Kelimeler: Graves hastalığı, Tedavi, Sabit doz, Iyot-131

Anahtar Kelimeler:

Graves hastalığı, Tedavi, Sabit doz, Iyot-131

-

Keywords:

-,

PDF

___

1. Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8:457-469.
2. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in he diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-135. doi: 10.1089/thy.1991.1.129.
3. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid 2010;20:785-793.
4. Panareo S, Rossi R, Fabbri S, et al. A practical method for the estimation of therapeutic activity in the treatment of Graves' hyperthyroidism. Q J Nucl Med Mol Imaging 2010;Epub ahead of print, PubMed ID- 21068711.
5. Marković V, Eterović D, Stipanović P, Punda A. Thyroid echogenicity: A clue to precise individual dosimetry in radioiodine therapy of hyperthyroidism. Med Hypotheses 2010; Epub ahead of print, PubMed ID- 20889262.
6. van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease. Hell J Nucl Med 2010;13:2-5.
7. Traino AC, Grosso M, Mariani G. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid massreduction based method for the optimum activity calculation. Phys Med 2010;26:71-79. doi:10.1016/j.ejmp.2009.08.003.
8. Collier A, Ghosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves' disease. Hormones (Athens) 2009;8:273-278.
9. Sanyal D, Mukhhopadhyay P, Pandit K, et al. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease. J Indian Med Assoc 2008;106:360-361.
10. Boelaert K, Syed AA, Manji N, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf) 2009;70:129-138. doi: 10.1111/j.1365.2008.03291.x
11. Canadas V, Vilar L, Moura E, Brito A, Castellar E. Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves' disease. Arq Bras Endocrinol Metabol 2007; 51:1069-1076.
12. Ustun F, Yuksel M, Durmus-Altun G, et al. The incidence of recurrence and hypothyroidism after radioiodine treatment in patients with hyperthyroidism in Trakya, a mild iodine deficiency area, during the period 1991-2003. Ann Nucl Med 2005;19:737-742. doi: 10.1007/BFO2985126.
13. Esfahani AF, Kakhki VR, Fallahi B, et al. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Hell J Nucl Med 2005;8:158-61.
14. Rapoport B, Caplan R, DeGroot LJ. Low-dose sodium iodide I 131 therapy in Graves disease. JAMA 1973;224:1610-1613.
15. Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1986;24:217-222. doi: 10.1111/j.1365.tb00765.x.
16. Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989;69:49-53. doi: 10.1210/jcem-69-1-49.